Fennec Pharmaceuticals Inc. FENC
13.61 USD +0.28 (+2.10%)
As ofNov 19, 2026, 2:11 PM EST
13.20 Day range 13.84
5.65 52-week range 13.85
- YTD
- +76.75%
- 1 year
- +66.38%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $17 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $17.
zacks.com Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable Adherex Technologies (FENC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed…
benzinga.com H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.benzinga.com B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19 B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $18 to $19.
zacks.com What Makes Adherex Technologies (FENC) a New Strong Buy Stock Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8% The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
seekingalpha.com Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
marketbeat.com Adherex Technologies Q3 Earnings Call Highlights Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and…
benzinga.com Fennec Pharmaceuticals Q3 2026 Earnings Call Transcript Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.benzinga.com Fennec Pharmaceuticals Q3 EPS $0.12 Beats $0.10 Estimate, Sales $19.608M Beat $18.401M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 700 percent increase over losses of…
globenewswire.com Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update ~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from…
